Cleveland Clinic's 20th Annual ASH Review

http://www.clevelandclinicmeded.com/live/courses/ashreview/

 

Cleveland Clinic's 20th Annual ASH Review
A

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 and for Which Pts? Does E1912 Suggest Ibrutinib Can Be Considered a Time Limited Therapy?

By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato
By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato
336 views
April 14, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Malignant Hematology
07:01
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of MDS: Clonal Hematopoiesis Increases Risk for Hema…

Feat. H. Carraway
26:41
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on MDS: Luspatercept Under FDA Review, Novel Oral HM…

Feat. H. Carraway
14:17
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Anemia in Myelofibrosis: Luspatercept Improvement…

Feat. S. Mukherjee
14:51
Cleveland Clinic's 20th Annual ASH Review

ASH 2019 Review on Treating Myelofibrosis in the Setting of Thromboc…

Feat. S. Mukherjee
06:37
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Limited Stage DLBCL: Can We Use PET Scan to Tailo…

Feat. B. Hill
08:38
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on R/R DLBCL: For Frail Unfit Patients, Addition of …

Feat. B. Hill
08:35
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on MCL: Can Anti-CD19 CAR-T Cell Therapy Be Used for…

Feat. B. Hill
06:19
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 an…

Feat. A. Mato
07:59
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Nov…

Feat. A. Mato
05:08
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Combinations or Sequences of Targeted Agents in C…

Feat. A. Mato
04:52
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow…

Feat. A. Mato
08:21
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Cov…

Feat. A. Mato
11:26
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review: Should High-risk Smoldering Myeloma Be Treated? Evi…

Feat. F. Anwer
05:49
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Newly Diagnosed Multiple Myeloma: VRD-Dara vs. VR…

Feat. F. Anwer
06:21
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Relapsed/Refractory: CAR T Cells - A New Frontier…

Feat. F. Anwer